Products for Research Use Only

APX-115

CAT: 0804-HY-120801-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-120801-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 effectively prevents kidney injury[1].
CAS Number
1395946-75-4
Product Name Alternative
Ewha-18278
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
NADPH Oxidase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/apx-115.html
Purity
99.90
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC1=C(CCC)C(C2=CC=CC=C2)=NN1C3=NC=CC=C3.Cl
Molecular Formula
C17H18ClN3O
Molecular Weight
315.80
Precautions
H302, H315, H319, H335
References & Citations
[1]Kwon G, et al. A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis. Oncotarget. 2017 Jun 16;8 (43) :74217-74232.|[2]Cha JJ, et al. APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury. Lab Invest. 2017 Apr;97 (4) :419-431.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
NOX1; NOX2; NOX4
Citation 01
Nat Immunol. 2021 Sep;22 (9) :1107-1117.|Biomed Rep. 2025 Jun 19;23 (3) :143.